{"id":1882,"date":"2024-08-30T21:56:32","date_gmt":"2024-08-30T19:56:32","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/bilim-ve-uygulamadan-haberler\/"},"modified":"2026-02-13T12:11:10","modified_gmt":"2026-02-13T11:11:10","slug":"bilim-ve-uygulamadan-haberler","status":"publish","type":"page","link":"https:\/\/studienportal-eierstockkrebs.de\/tr\/bilim-ve-uygulamadan-haberler\/","title":{"rendered":"Bilim ve uygulamadan haberler"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Haberler<\/strong>
Bilim ve uygulamadan haberler<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

ESGO 2026’dan \u00f6ne \u00e7\u0131kanlar ve yeni yetkilendirme!<\/a><\/h3><\/header>
\n

Kopenhag’daki ESGO’dayd\u0131k ve \u015eubat ay\u0131nda FDA onay\u0131 alan \u00e7al\u0131\u015fma sonu\u00e7lar\u0131n\u0131n sunumunu izledik! Platine diren\u00e7li yumurtal\u0131k kanseri i\u00e7in yeni bir se\u00e7enek olarak Keytruda + paklitaksel 10 \u015eubat 2026 tarihinde ABD G\u0131da...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Yeni nihai veriler: Atezolizumab ile imm\u00fcnoterapi, tekrarlayan yumurtal\u0131k kanserinde ek fayda sa\u011flam\u0131yor<\/a><\/h3><\/header>
\n

Yeni nihai veriler: Atezolizumab ile imm\u00fcnoterapi, tekrarlayan yumurtal\u0131k kanserinde ek fayda sa\u011flam\u0131yor AGO-OVAR 2.29 (ENGOT-ov34) \u00e7al\u0131\u015fmas\u0131n\u0131n nihai sonu\u00e7lar\u0131 Aral\u0131k 2025’te yay\u0131nlanm\u0131\u015ft\u0131r. Bu b\u00fcy\u00fck uluslararas\u0131 faz III \u00e7al\u0131\u015fmada, bevacizumab ve platin...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

AGO-OVAR 27- WoO<\/a><\/h3><\/header>
\n

AGO-OVAR 27 – WoO WoO: Histolojik olarak kan\u0131tlanm\u0131\u015f EOC’de olaparib ve durvalumab \u00fczerine F\u0131rsat Penceresi \u00e7al\u0131\u015fmas\u0131 AGO-ovar 27 \u00e7al\u0131\u015fmas\u0131n\u0131n A kohortu Ocak 2025’ten bu yana tamamen i\u015fe al\u0131nm\u0131\u015ft\u0131r. B kohortunda...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

\u00c7al\u0131\u015fma hedefine ula\u015f\u0131ld\u0131! – ROSELLA \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131<\/a><\/h3><\/header>
\n

Platine diren\u00e7li yumurtal\u0131k kanserinin tedavisine ili\u015fkin yeni bulgular – ROSELLA \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131 Ocak ay\u0131n\u0131n sonunda, ila\u00e7 \u015firketi Corcept Therapeutics, ROSELLA \u00e7al\u0131\u015fmas\u0131n\u0131n olumlu sonu\u00e7lar\u0131na ili\u015fkin bir bas\u0131n a\u00e7\u0131klamas\u0131 yay\u0131nlad\u0131! Bu \u00e7al\u0131\u015fmada...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Platine diren\u00e7li yumurtal\u0131k kanseri olan hastalar i\u00e7in haberler<\/a><\/h3><\/header>
\n

Hastalar i\u00e7in haberlerplatine diren\u00e7li yumurtal\u0131k kanseri ile \u0130la\u00e7 \u015firketi Eli Lilly k\u0131sa bir s\u00fcre \u00f6nce ABD G\u0131da ve \u0130la\u00e7 \u0130daresi adl\u0131 yeni bir ila\u00e7 i\u00e7in ABD G\u0131da ve \u0130la\u00e7 Dairesi’nden...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN<\/a><\/h3><\/header>
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN Platine duyarl\u0131 yumurtal\u0131k kanseri olan ve niraparib i\u00e7in kontrendikasyonu bulunmayan hastalar i\u00e7in Bu giri\u015fimsel olmayan g\u00f6zlemsel \u00e7al\u0131\u015fman\u0131n amac\u0131, ilk kez tan\u0131 konmu\u015f veya n\u00fcksetmi\u015f...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

\u0130fade XVIII (18)<\/a><\/h3><\/header>
\n

NOGGO S30\/ \u0130fade XVIII (18) JI\u0307NEKOLOJI\u0307K T\u00dcM\u00d6RL\u00dc HASTALAR \u00dcZERI\u0307NDE KRI\u0307ZLERI\u0307N ETKI\u0307SI\u0307NE I\u0307LI\u0307\u015eKI\u0307N ULUSLARARASI ARA\u015eTIRMA Anksiyete, jinekolojik hastal\u0131klar\u0131 olan kanser hastalar\u0131 i\u00e7in merkezi bir konudur ve sava\u015f, mali durum ve pandemi...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

IFADE IX (9)<\/a><\/h3><\/header>
\n

NOGGO S20 \/ ENGOTgyn4 – EXPRESSION IX (9) Jinekolojik kanserde uzun s\u00fcreli sa\u011fkal\u0131m \/ Jinekolojik kanserde uzun s\u00fcreli sa\u011fkalanlar Yumurtal\u0131k kanserinden uzun s\u00fcreli kurtulanlara odaklanan bir anket olan Expression VI...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO S19 – I\u0307FADE VIII (8)<\/a><\/h3><\/header>
\n

NOGGO S19 – I\u0307FADE VIII (8) D\u00fc\u015f\u00fck dereceli yumurtal\u0131k karsinomu (grup A) veya s\u0131n\u0131rda yumurtal\u0131k t\u00fcm\u00f6r\u00fc (grup B – kapal\u0131) olan hastalar i\u00e7in. Ser\u00f6z over karsinomu iyi diferansiye (d\u00fc\u015f\u00fck dereceli...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

IFADE VI (6)<\/a><\/h3><\/header>
\n

NOGGO S13 \/ ENGOT-ov40 – EXPRESSION VI (6)CAROLIN HANNA \u0130LE TANI\u015eIYOR En az 5 y\u0131l \u00f6nce te\u015fhis edilmi\u015f yumurtal\u0131k, fallop t\u00fcp\u00fc ve periton kanseri olan hastalar i\u00e7in YEN\u0130: Daha \u00f6nce...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

ENGOT-ov83 \/ CATALINA-2<\/a><\/h3><\/header>
\n

ENGOT-ov83 \/ CATALINA-2 \u0130lerlemi\u015f, platine diren\u00e7li yumurtal\u0131k kanseri hastalar\u0131nda yeni bile\u015fik TORL-1-23’\u00fcn etkinli\u011fini ve g\u00fcvenli\u011fini de\u011ferlendirmek i\u00e7in terap\u00f6tik \u00e7al\u0131\u015fma CATALINA-2 , ilerlemi\u015f, platine diren\u00e7li yumurtal\u0131k kanseri (yumurtal\u0131k, fallop t\u00fcp\u00fc veya...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

ENGOT-ov47-TR\/ NOGGO-TR2 – YARDIM-ER<\/a><\/h3><\/header>
\n

ENGOT-ov47-TR\/ NOGGO-TR2 – YARDIM-ER YUMURTALIK KANSERI\u0307NI\u0307N I\u0307LK N\u00dcKS\u00dc OLAN HASTALARIN KANINDAKI\u0307 HE4 SERUM D\u00dcZEYLERI\u0307 \u00dcZERI\u0307NE G\u00d6ZLEMSEL \u00c7ALI\u015eMA HELP-ER \u00e7al\u0131\u015fmas\u0131, platine duyarl\u0131 yumurtal\u0131k kanserinin ilk n\u00fcksetmesi olan hastalar\u0131n tedavisini iyile\u015ftirmek i\u00e7in...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301<\/a><\/h3><\/header>
\n

AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301 TEKRARLAYAN D\u00dc\u015e\u00dcK DERECELI\u0307 SER\u00d6Z OVER KARSI\u0307NOMU \u00dcZERI\u0307NE KLI\u0307NI\u0307K \u00c7ALI\u015eMA AGO-OVAR 2.46 \/ ENGOT-ov81 \/ RAMP 301, tekrarlayan d\u00fc\u015f\u00fck dereceli ser\u00f6z over kanseri (LGSOC)...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO ov54 – SCOUT-1<\/a><\/h3><\/header>
\n

NOGGO ov54 – \u0130zci 1 Ba\u015flang\u0131\u00e7 tedavisi g\u00f6ren yumurtal\u0131k kanserli hastalar\u0131n g\u00fcnl\u00fck rutinlerinden veri toplamaya y\u00f6nelik g\u00f6zlemsel \u00e7al\u0131\u015fma SCOUT-1, yumurtal\u0131k kanserli hastalar\u0131n g\u00fcnl\u00fck rutininden klinik ve hasta taraf\u0131ndan bildirilen verileri...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

N-PLUS<\/a><\/h3><\/header>
\n

NOGGO ov53\/ ENGOT-ov62 – N-Plus T\u00fcm\u00f6rs\u00fcz cerrahi ge\u00e7irmi\u015f hastalarda kemoterapi d\u00f6ng\u00fclerinin say\u0131s\u0131n\u0131 ve dolay\u0131s\u0131yla kemoterapi s\u00fcresini azaltmay\u0131 ama\u00e7layan d\u00fcnyan\u0131n ilk \u00e7al\u0131\u015fmas\u0131. N-Plus, ilerlemi\u015f yumurtal\u0131k kanseri i\u00e7in ba\u015flang\u0131\u00e7 tedavisi g\u00f6ren HRD-pozitif...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NIS CAROLIN<\/a><\/h3><\/header>
\n

NIS Niraparib – NOGGO-ov45 – CAROLIN Platine duyarl\u0131 yumurtal\u0131k kanseri olan ve niraparib i\u00e7in kontrendikasyonu bulunmayan hastalar i\u00e7in Bu giri\u015fimsel olmayan g\u00f6zlemsel \u00e7al\u0131\u015fman\u0131n amac\u0131, ilk kez tan\u0131 konmu\u015f veya n\u00fcksetmi\u015f...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO S15 – FraStROC<\/a><\/h3><\/header>
\n

NOGGO S15 – FraStROC Tekrarlayan veya n\u00fckseden yumurtal\u0131k kanseri olan hastalar i\u00e7in \u00e7al\u0131\u015fma. TEKRARLAYAN VEYA N\u00dcKSEDEN YUMURTALIK KANSERI OLAN HASTALAR I\u00c7IN \u00c7ALI\u015eMA FraStROC \u00e7al\u0131\u015fmas\u0131, yumurtal\u0131k kanseri hastalar\u0131n\u0131n kemoterapi s\u0131ras\u0131nda n\u00fcks...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

AGO-OVAR 28 \/ ENGOT-OV57<\/a><\/h3><\/header>
\n

AGO-OVAR 28 \/ ENGOT-OV57 Yeni tan\u0131 konmu\u015f ileri evre yumurtal\u0131k kanseri i\u00e7in kemoterapi alan hastalarda tek ba\u015f\u0131na niraparib ile niraparib ve bevacizumab kombinasyonunu de\u011ferlendiren randomize a\u00e7\u0131k etiketli bir faz III...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

IFADE XX (20)<\/a><\/h3><\/header>
\n

NOGGO S33\/ \u0130fade XX (20) JI\u0307NEKOLOJI\u0307K T\u00dcM\u00d6R\u00dc OLAN HASTALARA K\u00d6T\u00dc HABER VERI\u0307LMESI\u0307NE I\u0307LI\u0307\u015eKI\u0307N ANKET K\u00f6t\u00fc haber vermek, \u00f6zellikle jinekolojik onkolojide g\u00fcnl\u00fck t\u0131bbi uygulamalar\u0131n \u00f6nemli bir par\u00e7as\u0131d\u0131r. Bu konu\u015fmalar\u0131n s\u0131kl\u0131\u011f\u0131na ra\u011fmen,...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

ESMO 2025’ten yeni \u00e7al\u0131\u015fma verileri – \u0130mm\u00fcnoterapi platine diren\u00e7li yumurtal\u0131k kanserinde ilk kez sa\u011fkal\u0131m faydas\u0131 sa\u011fl\u0131yor<\/a><\/h3><\/header>
\n

ESMO 2025’ten yeni \u00e7al\u0131\u015fma verileri\u0130mm\u00fcnoterapi, platine diren\u00e7li yumurtal\u0131k kanserinde ilk sa\u011fkal\u0131m faydas\u0131n\u0131 sa\u011fl\u0131yor ENGOT-ov65\/KEYNOTE-B96 \u00e7al\u0131\u015fmas\u0131n\u0131n ilk sonu\u00e7lar\u0131na ili\u015fkin bir bas\u0131n b\u00fclteni May\u0131s 2025’te yay\u0131nlanm\u0131\u015f ve en son umut verici sonu\u00e7lar...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Yumurtal\u0131k kanseri i\u00e7in en \u00f6nemli ASCO sonu\u00e7lar\u0131<\/a><\/h3><\/header>
\n

Yumurtal\u0131k kanseri i\u00e7in en \u00f6nemli ASCO sonu\u00e7lar\u0131 2025 D\u00fcn, ASCO 2025’ten yumurtal\u0131k kanseri \u00fczerine \u00f6nemli \u00e7al\u0131\u015fmalar\u0131n sunuldu\u011fu 26. NOGGO Jinekolojik Onkoloji G\u00fcncellemesi ger\u00e7ekle\u015fti. Biz de oradayd\u0131k ve en \u00f6nemli bulgular\u0131...<\/p>Daha fazla bilgi edinin<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

HaberlerBilim ve uygulamadan haberler Studienziel erreicht! \u2013 Ergebnisse der ROSELLA-Studie Neue Erkenntnisse zur Behandlung von platinresistentem Eierstockkrebs \u2013 Ergebnisse der ROSELLA-Studie Ende Januar ver\u00f6ffentlichte der Pharmakonzern Corcept Therapeutics eine Pressemitteilung zu den positiven Studienergebnissen der ROSELLA Studie! Diese Studie hat… Daha fazla bilgi edinin Neuigkeiten f\u00fcr Patientinnen mit platinresistentem Eierstockkrebs Neuigkeiten f\u00fcr Patientinnen mit platinresistentem […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1882","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/pages\/1882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/comments?post=1882"}],"version-history":[{"count":3,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/pages\/1882\/revisions"}],"predecessor-version":[{"id":1896,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/pages\/1882\/revisions\/1896"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/media?parent=1882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}